Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Enlivex Therapeutics Ltd.
DescriptionAutologous or donor cells manipulated ex vivo to begin early stages of apoptosis
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationGraft-versus-host disease (GvHD)
Indication DetailsPrevent graft-versus-host disease (GvHD); Treat graft-versus-host disease (GvHD)
Regulatory Designation U.S. - Orphan Drug (Prevent graft-versus-host disease (GvHD));
U.S. - Orphan Drug (Treat graft-versus-host disease (GvHD));
EU - Orphan Drug (Prevent graft-versus-host disease (GvHD))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today